Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF1806
- Development stage
- Preclinical
- Lead developer
- ImmunoForge
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Administration
- Subcutaneous
01
Overview
PF1806 is a long-acting biologic therapeutic being developed by ImmunoForge for the treatment of Short Bowel Syndrome (SBS). The drug consists of a glucagon-like peptide-2 (GLP-2) analogue, specifically teduglutide, genetically fused to ImmunoForge's proprietary Elastin-Like Polypeptide (ELP) platform. This fusion technology is designed to significantly extend the drug's half-life, potentially enabling a once-weekly dosing schedule compared to the daily injections required by current GLP-2 therapies. By agonizing the GLP-2 receptor (GLP-2R), PF1806 promotes intestinal adaptation, increases villus height, and enhances nutrient absorption. Preclinical studies have demonstrated that this fusion protein has a significantly greater effect on small intestine growth in normal rats compared to teduglutide alone.
- Other names
- GLP-2-ELP fusion proteinGLP2-ELP fusion proteinGLP 2-ELP fusion proteinGLP-2-ELPGLP2-ELPGLP 2-ELPteduglutide-ELP fusion
02
Targets
GLP2R (Glucagon-like peptide 2 receptor)
Beyond the preview
Go deeper on PF1806.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF1806.